BRPI0408167A - conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais - Google Patents
conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiaisInfo
- Publication number
- BRPI0408167A BRPI0408167A BRPI0408167-6A BRPI0408167A BRPI0408167A BR PI0408167 A BRPI0408167 A BR PI0408167A BR PI0408167 A BRPI0408167 A BR PI0408167A BR PI0408167 A BRPI0408167 A BR PI0408167A
- Authority
- BR
- Brazil
- Prior art keywords
- polysaccharide
- protein
- immunization against
- staphylococcal surface
- nosocomial infections
- Prior art date
Links
- 206010011409 Cross infection Diseases 0.000 title abstract 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 title abstract 2
- 230000003053 immunization Effects 0.000 title abstract 2
- 238000002649 immunization Methods 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 abstract 3
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 244000052769 pathogen Species 0.000 abstract 2
- 229920001282 polysaccharide Polymers 0.000 abstract 2
- 239000005017 polysaccharide Substances 0.000 abstract 2
- 241000191967 Staphylococcus aureus Species 0.000 abstract 1
- 241000191963 Staphylococcus epidermidis Species 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002482 oligosaccharides Polymers 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
"CONJUGADOS DE POLISSACARìDEO-PROTEìNA VEìCULO ADESINA DA SUPERFìCIE ESTAFILOCóCICA PARA IMUNIZAçãO CONTRA INFECçõES NOSOCOMIAIS". A presente invenção refere-se a conjugados imunogênicos de polissacarídeo-proteína tendo um antígeno de polissacarídeo (ou seu fragmento de oligossacarídeo representando um ou mais epitopos antigênicos) derivado de um agente patogênico nosocomial conjugado a uma proteína veículo adesina da superfície estafilocócica que são usados em composições imunogênicas para estimular respostas de anticorpo ao antígeno de polissacarídeo e à proteína veículo adesão da superfície estafilocócica. Tais composições imunogênicas são usadas para imunizar contra doenças causadas por Staphylococcus aureus, Staphylococcus epidermidis ou outros agentes patogênicos nosocomiais.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45272803P | 2003-03-07 | 2003-03-07 | |
US60/452,728 | 2003-03-07 | ||
PCT/US2004/006661 WO2004080490A2 (en) | 2003-03-07 | 2004-03-04 | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0408167A true BRPI0408167A (pt) | 2006-03-21 |
BRPI0408167B1 BRPI0408167B1 (pt) | 2014-10-21 |
Family
ID=32990675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0408167-6B1A BRPI0408167B1 (pt) | 2003-03-07 | 2004-03-04 | Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais |
Country Status (12)
Country | Link |
---|---|
US (2) | US9296795B2 (pt) |
EP (1) | EP1601381A2 (pt) |
JP (2) | JP5102487B2 (pt) |
KR (1) | KR20060035581A (pt) |
CN (2) | CN1787839B (pt) |
AU (1) | AU2004220590B2 (pt) |
BR (1) | BRPI0408167B1 (pt) |
CA (1) | CA2517439C (pt) |
MX (1) | MXPA05009351A (pt) |
NZ (1) | NZ561879A (pt) |
WO (1) | WO2004080490A2 (pt) |
ZA (1) | ZA200508086B (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1565478B1 (en) | 2002-11-12 | 2017-08-02 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
NZ561879A (en) | 2003-03-07 | 2009-05-31 | Wyeth Corp | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
JP4764830B2 (ja) * | 2003-12-17 | 2011-09-07 | ワイス・エルエルシー | 免疫原性ペプチド担体コンジュゲートおよびその生産法 |
EP2460813A1 (en) * | 2003-12-17 | 2012-06-06 | Janssen Alzheimer Immunotherapy | A beta immunogenic peptide carrier conjugates and methods of producing same |
EP1804833A2 (en) * | 2004-09-22 | 2007-07-11 | GlaxoSmithKline Biologicals SA | Staphylococcal immunogenic compositions |
FR2884830A1 (fr) | 2005-04-25 | 2006-10-27 | Sanofi Pasteur Sa | Procede de production de souches de staphylococcus aureus surproductrices |
GB0526038D0 (en) * | 2005-12-21 | 2006-02-01 | Glaxosmithkline Biolog Sa | Immunogenic composition |
EP2476433A1 (en) * | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
AR060188A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Procedimiento de conjugacion |
PE20120262A1 (es) * | 2006-03-30 | 2012-03-30 | Glaxosmithkline Biolog Sa | Procedimiento para la preparacion de inmunoconjugados que comprenden polisacarido u oligosacarido capsular de s. aureus junto con la proteina portadora |
FR2899110A1 (fr) | 2006-03-31 | 2007-10-05 | Sanofi Pasteur Sa | Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus |
KR100829257B1 (ko) * | 2006-06-22 | 2008-05-14 | 부경대학교 산학협력단 | 인간 섬유육종세포에서 메트릭스 메탈로프로테이나제-9의발현 및 활성을 억제하는 카복시화 글루코사민 화합물 및이를 함유한 메트릭스 메탈로프로테이나제-9 억제제 |
KR100780868B1 (ko) | 2006-07-10 | 2007-11-30 | 부경대학교 산학협력단 | 항암효과를 나타내는 4급 아미노 글루코사민 화합물 |
GB0700136D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
EP2666784B1 (en) * | 2007-08-31 | 2017-04-05 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
WO2009127677A1 (en) * | 2008-04-16 | 2009-10-22 | Glaxosmithkline Biologicals S.A. | Vaccine |
DK2315747T3 (en) | 2008-07-21 | 2018-02-26 | Brigham & Womens Hospital Inc | Methods and Compositions of Synthetic Beta-1.6 Glucosamine Oligosaccharides |
US9125951B2 (en) * | 2009-06-22 | 2015-09-08 | Wyeth Llc | Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
SI2445522T1 (sl) | 2009-06-22 | 2017-10-30 | Wyeth Llc | Imunogeni sestavki antigenov Staphylococcusa aureusa |
NZ616921A (en) | 2009-07-15 | 2015-06-26 | Genentech Inc | Gram-positive bacteria specific binding compounds |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
JP2013506651A (ja) | 2009-09-30 | 2013-02-28 | ノバルティス アーゲー | Staphylococcus.aureus5型および8型莢膜多糖の結合体 |
PL2493498T3 (pl) | 2009-10-30 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8 |
CA2819120C (en) | 2010-12-22 | 2016-07-05 | Wyeth Llc | Stable immunogenic compositions of staphylococcus aureus antigens |
CN102759618A (zh) * | 2012-07-18 | 2012-10-31 | 成都欧林生物科技股份有限公司 | 用ELISA法检测血清中Hib多糖抗体含量的方法 |
MX363511B (es) | 2012-08-16 | 2019-03-26 | Pfizer | Proceso de glucoconjugación y composiciones. |
HRP20221438T1 (hr) | 2012-12-20 | 2023-02-03 | Pfizer Inc. | Postupak glikokonjugiranja |
GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
DK3010535T3 (da) * | 2013-06-19 | 2020-11-30 | Integrated Biotherapeutics Inc | Toxoide peptider afledt fra fenol opløselige modulin, delta toxin, superantigener og fusioner deraf |
JP2016540764A (ja) * | 2013-12-04 | 2016-12-28 | グリコヴァキシン アーゲー | 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防 |
US10668164B2 (en) | 2014-02-14 | 2020-06-02 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
MX2017007652A (es) | 2014-12-10 | 2017-10-11 | Glaxosmithkline Biologicals Sa | Metodo de tratamiento. |
EP3292146A1 (en) | 2015-05-04 | 2018-03-14 | Pfizer Inc | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
US11446371B2 (en) | 2015-11-05 | 2022-09-20 | The Texas A&M University System | Targeting of ligand binding sites in ClfA |
CN106084037B (zh) * | 2016-06-08 | 2020-01-07 | 中国人民解放军第二军医大学 | 一种炭疽杆菌荚膜表面三糖缀合物及其制备方法和应用 |
CN106366163A (zh) * | 2016-10-31 | 2017-02-01 | 中国人民解放军第二军医大学 | 一种β‑1,2‑D‑寡聚甘露糖肽‑蛋白缀合物及其制备方法和应用 |
TW201925222A (zh) * | 2017-06-23 | 2019-07-01 | 美商醫院疫苗公司 | 免疫原性組成物 |
CA3069747A1 (en) | 2017-07-27 | 2019-01-31 | Mohammad Javad Aman | Immunogenic composition comprising a fusion peptide derived from superantigen toxoids |
CN110484773B (zh) * | 2019-09-12 | 2020-06-23 | 江苏沃钛有色金属有限公司 | 一种钛合金基材及其制备方法 |
JP2023526780A (ja) | 2020-05-01 | 2023-06-23 | 神州細胞工程有限公司 | タンパク質/ペプチド抗原の免疫原性を向上させる方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5189015A (en) | 1984-05-30 | 1993-02-23 | Alfa-Laval Agri International Ab | Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability |
SE454403B (sv) | 1984-05-30 | 1988-05-02 | Alfa Laval Agri Int | Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel |
IL78775A (en) * | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
US5571514A (en) | 1987-06-01 | 1996-11-05 | Alfa Laval Ab | Fibronectin binding protein as well as its preparation |
US5320951A (en) | 1987-06-01 | 1994-06-14 | Hoeoek Magnus | Fibronectin binding protein as well as its preparation |
SE8801894D0 (sv) | 1988-05-20 | 1988-05-20 | Alfa Laval Agri Int | Fibronektinbindande protein |
SE8901687D0 (sv) | 1989-05-11 | 1989-05-11 | Alfa Laval Agri Int | Fibronectin binding protein as well as its preparation |
US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
US5440014A (en) | 1990-08-10 | 1995-08-08 | H+E,Uml/Oo/ K; Magnus | Fibronectin binding peptide |
US5851794A (en) | 1990-10-22 | 1998-12-22 | Alfa Laval Ab | Collagen binding protein as well as its preparation |
US5980908A (en) | 1991-12-05 | 1999-11-09 | Alfa Laval Ab | Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment |
US20020173462A1 (en) * | 1992-09-21 | 2002-11-21 | Boden Wastfelt Maria K. | Fibrinogen binding protein |
IL107458A0 (en) * | 1992-11-02 | 1994-02-27 | Gen Hospital Corp | Conjugate vaccine against group b streptococcus |
ATE254475T1 (de) | 1993-09-22 | 2003-12-15 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
US5648240A (en) | 1994-05-24 | 1997-07-15 | Texas A&M University | MHC II analog from Staphylococcus aureus |
US6008341A (en) | 1994-08-22 | 1999-12-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
US6994855B1 (en) | 1994-08-22 | 2006-02-07 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
CA2255669A1 (en) | 1996-05-16 | 1997-11-20 | The Texas A & M University System | Collagen binding protein compositions and methods of use |
SE9602496D0 (sv) | 1996-06-20 | 1996-06-20 | Bengt Guss | Method and means for producing a fibrinogen binding protein and its use in biotechnology |
WO1999003871A1 (en) * | 1997-07-17 | 1999-01-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hexadecasaccharide-protein conjugate vaccine for shigella dysenteriae type 1 |
US7252828B2 (en) * | 1998-07-15 | 2007-08-07 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
WO2000012689A1 (en) | 1998-08-31 | 2000-03-09 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Polypeptides and polynucleotides from coagulase-negative staphylococci |
ATE422368T1 (de) * | 1998-08-31 | 2009-02-15 | Inhibitex Inc | Multikomponenten impfstoffe gegen staphylococcus aureus |
US6703025B1 (en) | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
AU5408099A (en) | 1998-09-01 | 2000-03-21 | John F. Wetling | Electrically treated composition and use thereof |
EP1034792A1 (en) * | 1999-03-11 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Intranasal delivery of pneumococcal polysaccharide vaccines |
EP1035137A1 (en) * | 1999-03-12 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Method for the reductive amination of polysaccharides |
JP4846906B2 (ja) * | 1999-03-19 | 2011-12-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
WO2000071585A1 (en) * | 1999-05-03 | 2000-11-30 | Medarex, Inc. | Human antibodies to staphylococcus aureus |
DE19937864C2 (de) * | 1999-08-13 | 2002-10-31 | Rudolf Marx | Werkstück und Verfahren zum Herstellen und zum Verwerten des Werkstückes |
EP2298736B1 (en) * | 2000-03-22 | 2015-07-15 | Solulink, Inc. | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents |
GB0007432D0 (en) * | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
MXPA03006561A (es) | 2001-01-23 | 2004-10-15 | Aventis Pasteur | Vacuna del conjugado proteina-polisacarido meningococico, multivalente. |
EP2339344A1 (en) | 2001-06-15 | 2011-06-29 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
CA2351018A1 (en) * | 2001-07-09 | 2003-01-09 | Universite De Sherbrooke | Dna vaccine against staphylococcus aureus |
US20030113350A1 (en) * | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
JP2005536185A (ja) | 2002-03-05 | 2005-12-02 | インヒビテックス インコーポレーテッド | コアグラーゼ陰性ブドウ球菌タンパク質を認識するモノクローナルおよびポリクローナル抗体 |
NZ561879A (en) | 2003-03-07 | 2009-05-31 | Wyeth Corp | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
-
2004
- 2004-03-04 NZ NZ561879A patent/NZ561879A/en not_active IP Right Cessation
- 2004-03-04 US US10/548,507 patent/US9296795B2/en active Active
- 2004-03-04 CN CN2004800122658A patent/CN1787839B/zh not_active Expired - Fee Related
- 2004-03-04 KR KR1020057016646A patent/KR20060035581A/ko not_active Application Discontinuation
- 2004-03-04 CN CN201110225310.XA patent/CN102366630B/zh not_active Expired - Fee Related
- 2004-03-04 MX MXPA05009351A patent/MXPA05009351A/es active IP Right Grant
- 2004-03-04 AU AU2004220590A patent/AU2004220590B2/en not_active Ceased
- 2004-03-04 EP EP04717417A patent/EP1601381A2/en not_active Withdrawn
- 2004-03-04 WO PCT/US2004/006661 patent/WO2004080490A2/en active Application Filing
- 2004-03-04 JP JP2006509140A patent/JP5102487B2/ja not_active Expired - Fee Related
- 2004-03-04 CA CA2517439A patent/CA2517439C/en not_active Expired - Fee Related
- 2004-03-04 BR BRPI0408167-6B1A patent/BRPI0408167B1/pt not_active IP Right Cessation
-
2005
- 2005-10-06 ZA ZA200508086A patent/ZA200508086B/xx unknown
-
2006
- 2006-11-07 US US11/593,481 patent/US8377451B2/en active Active
-
2011
- 2011-10-18 JP JP2011228995A patent/JP5757841B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2012051922A (ja) | 2012-03-15 |
AU2004220590A1 (en) | 2004-09-23 |
CN102366630A (zh) | 2012-03-07 |
JP5102487B2 (ja) | 2012-12-19 |
MXPA05009351A (es) | 2006-03-08 |
US20070087014A1 (en) | 2007-04-19 |
CA2517439C (en) | 2013-07-23 |
US20070141077A1 (en) | 2007-06-21 |
KR20060035581A (ko) | 2006-04-26 |
CN102366630B (zh) | 2015-04-01 |
JP5757841B2 (ja) | 2015-08-05 |
CA2517439A1 (en) | 2004-09-23 |
WO2004080490A3 (en) | 2004-10-28 |
US8377451B2 (en) | 2013-02-19 |
EP1601381A2 (en) | 2005-12-07 |
AU2004220590B2 (en) | 2010-02-18 |
JP2006519870A (ja) | 2006-08-31 |
CN1787839B (zh) | 2011-09-28 |
CN1787839A (zh) | 2006-06-14 |
NZ561879A (en) | 2009-05-31 |
WO2004080490A2 (en) | 2004-09-23 |
US9296795B2 (en) | 2016-03-29 |
ZA200508086B (en) | 2010-04-28 |
BRPI0408167B1 (pt) | 2014-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0408167A (pt) | conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais | |
WO2006065553A3 (en) | Glycoconjugate vaccines containing peptidoglycan | |
BRPI0407101A (pt) | Vacinas meningocócicas mucosais | |
MX2021015775A (es) | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos. | |
CL2010000397A1 (es) | Composicion que provee inmunidad protectora contra micoplasma hyopneumoniae que comprende una cantidad inmunizante de dicha bacteria, al menos otro antigeno viral o bacteriano, un adyuvante y un vehiculo farmaceutico, util para lograr proteccion inmune en animales. (divisional de solicitud 2003-00957) | |
Péchiné et al. | Targeting Clostridium difficile surface components to develop immunotherapeutic strategies against Clostridium difficile infection | |
BR0310042A (pt) | Vacinas de combinação mucosal para meningite bacteriana | |
ATE552844T1 (de) | Injizierbarer impfstoff gegen multiple meningokokken-serogruppen | |
KR920003982A (ko) | 면역원성 콘쥬게이트 및 이를 함유하는 백신 조성물 | |
BRPI0009163B8 (pt) | composição imunogênica e vacina que a compreende | |
DE60230670D1 (de) | Staphylococcus aureus exopolysaccharid und verfahren | |
PE20071058A1 (es) | Vacuna de streptococcus pneumoniae | |
ATE198051T1 (de) | Pneumokokken-polysaccharid-rekombinante- pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen | |
BR0207068A (pt) | Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus | |
WO1998057994A3 (en) | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria | |
CY1113020T1 (el) | Εμβολια συνδυασμου για neisseria meningitidis | |
BRPI0612670B8 (pt) | composição imunogênica, vacina a compreendendo e kit de vacina para a administração concomitante ou sequencial | |
Maira-Litran et al. | Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A | |
BRPI0408085A (pt) | composição e método para o tratamento e prevenção de infecções entéricas bacterianas | |
TW200716670A (en) | Use of panton-valentine leukocidin for treating and preventing staphylococcus infections | |
BRPI0410341B8 (pt) | conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina | |
EA202091690A1 (ru) | Иммуногенная композиция, содержащая стафилококковые антигены | |
MA45283A1 (fr) | Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela | |
BRPI0510659A (pt) | indução de uma resposta imunológica contra polissacarìdeos de streptococcus pneumoniae | |
MX2023013434A (es) | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 47/48, 39/385; C07K 16/12; A61P 37/00, 37/04 Ipc: A61K 47/48 (2011.01), A61K 39/385 (2011.01), C07K |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 47/48 , A61K 39/385 , C07K 16/12 , A61P 37/00 , A61P 37/04 Ipc: A61K 39/085 (2006.01), A61K 39/385 (2006.01), C07K |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/10/2014, OBSERVADAS AS CONDICOES LEGAIS. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time | ||
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |